TipRanks
Alkermes (ALKS)
NASDAQ:ALKS
US Market
ALKS
Alkermes
RESEARCH TOOLSreports
Want to see ALKS full AI Analyst Report?

Alkermes (ALKS) Stock Forecast & Price Target

642 Followers
See the Price Targets and Ratings of:

ALKS Analyst Ratings

Moderate Buy
14Ratings
Moderate Buy
10 Buy
3 Hold
1 Sell
Based on 14 analysts giving stock ratings to
Alkermes
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ALKS Stock 12 Month Forecast

Average Price Target

$58.77
▲(19.43% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $58.77 with a high forecast of $83.00 and a low forecast of $38.00. The average price target represents a 19.43% change from the last price of $49.21.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","55":"$55","84":"$84","40.5":"$40.5","69.5":"$69.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$83.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.76923076923077,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$58.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,40.5,55,69.5,84],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.54,43.80615384615385,47.07230769230769,50.33846153846154,53.604615384615386,56.87076923076923,60.136923076923075,63.403076923076924,66.66923076923077,69.9353846153846,73.20153846153846,76.46769230769232,79.73384615384614,{"y":83,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.54,41.94224852071006,43.34449704142012,44.74674556213017,46.14899408284023,47.55124260355029,48.95349112426035,50.35573964497041,51.75798816568047,53.16023668639053,54.56248520710059,55.964733727810646,57.366982248520706,{"y":58.76923076923077,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.54,40.34461538461538,40.14923076923077,39.95384615384615,39.75846153846154,39.56307692307692,39.36769230769231,39.17230769230769,38.97692307692308,38.78153846153846,38.58615384615385,38.39076923076923,38.19538461538461,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.98,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.96,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.25,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.05,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.38,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.27,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.72,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.99,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.2,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.54,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$83.00Average Price Target$58.77Lowest Price Target$38.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on ALKS
Ami Fadia
Needham
Needham
$62
Buy
25.99%
Upside
Reiterated
10/19/26
Alkermes (ALKS) Receives a Buy from Needham
Piper Sandler Analyst forecast on ALKS
David Amsellem
Piper Sandler
Piper Sandler
$65
Buy
32.09%
Upside
Reiterated
10/19/26
Analysts' Top Healthcare Picks: Alkermes (ALKS), BridgeBio Pharma (BBIO)
Truist Financial Analyst forecast on ALKS
Alex Nackenoff
Truist Financial
Not Ranked
Truist Financial
$55
Buy
11.77%
Upside
Initiated
10/16/26
Alkermes reinstated with a Buy at TruistAlkermes reinstated with a Buy at Truist
Bank of America Securities Analyst forecast on ALKS
Jason Gerberry
Bank of America Securities
Bank of America Securities
$38
Sell
-22.78%
Downside
Reiterated
10/09/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Alkermes (NASDAQ: ALKS)
RBC Capital Analyst forecast on ALKS
Leonid Timashev
RBC Capital
RBC Capital
$56
Buy
13.80%
Upside
Reiterated
10/08/26
Alkermes (ALKS) Receives a Buy from RBC Capital
Stifel Nicolaus Analyst forecast on ALKS
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$63
Buy
28.02%
Upside
Reiterated
10/05/26
Analysts Are Bullish on These Healthcare Stocks: Alkermes (ALKS), MoonLake Immunotherapeutics (MLTX)
Goldman Sachs Analyst forecast on ALKS
Andrea Newkirk
Goldman Sachs
Goldman Sachs
$50
Hold
1.61%
Upside
Initiated
09/24/26
Alkermes (ALKS) Gets a Hold from Goldman Sachs
Mizuho Securities Analyst forecast on ALKS
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$65
Buy
32.09%
Upside
Reiterated
09/22/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: AnaptysBio (NASDAQ: ANAB), Alkermes (NASDAQ: ALKS) and Iradimed (NASDAQ: IRMD)
Jefferies Analyst forecast on ALKS
Akash Tewari
Jefferies
Jefferies
$78→$83
Buy
68.66%
Upside
Reiterated
09/22/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Robert W. Baird Analyst forecast on ALKS
Luke Herrmann
Robert W. Baird
Robert W. Baird
$58→$61
Buy
23.96%
Upside
Reiterated
09/22/26
Alkermes price target raised to $61 from $58 at BairdAlkermes price target raised to $61 from $58 at Baird
H.C. Wainwright Analyst forecast on ALKS
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$43
Hold
-12.62%
Downside
Reiterated
09/21/26
Alkermes: Orexin Franchise Proof-of-Concept Supports Balanced Risk-Reward; Hold Rating Reiterated with Unchanged $43 Price Target
J.P. Morgan Analyst forecast on ALKS
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Hold
―
Reiterated
09/21/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Wells Fargo Analyst forecast on ALKS
Benjamin Burnett
Wells Fargo
Wells Fargo
$65
Buy
32.09%
Upside
Assigned
07/29/26
Wells Fargo Gives a Buy Rating to Alkermes (ALKS)
TD Cowen Analyst forecast on ALKS
Joseph Thome
TD Cowen
TD Cowen
$57→$58
Buy
17.86%
Upside
Reiterated
07/28/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on ALKS
Ashwani Verma
UBS
UBS
$42→$48
Buy
-2.46%
Downside
Reiterated
05/06/26
Alkermes price target raised to $48 from $42 at UBSAlkermes price target raised to $48 from $42 at UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on ALKS
Ami Fadia
Needham
Needham
$62
Buy
25.99%
Upside
Reiterated
10/19/26
Alkermes (ALKS) Receives a Buy from Needham
Piper Sandler Analyst forecast on ALKS
David Amsellem
Piper Sandler
Piper Sandler
$65
Buy
32.09%
Upside
Reiterated
10/19/26
Analysts' Top Healthcare Picks: Alkermes (ALKS), BridgeBio Pharma (BBIO)
Truist Financial Analyst forecast on ALKS
Alex Nackenoff
Truist Financial
Not Ranked
Truist Financial
$55
Buy
11.77%
Upside
Initiated
10/16/26
Alkermes reinstated with a Buy at TruistAlkermes reinstated with a Buy at Truist
Bank of America Securities Analyst forecast on ALKS
Jason Gerberry
Bank of America Securities
Bank of America Securities
$38
Sell
-22.78%
Downside
Reiterated
10/09/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Alkermes (NASDAQ: ALKS)
RBC Capital Analyst forecast on ALKS
Leonid Timashev
RBC Capital
RBC Capital
$56
Buy
13.80%
Upside
Reiterated
10/08/26
Alkermes (ALKS) Receives a Buy from RBC Capital
Stifel Nicolaus Analyst forecast on ALKS
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$63
Buy
28.02%
Upside
Reiterated
10/05/26
Analysts Are Bullish on These Healthcare Stocks: Alkermes (ALKS), MoonLake Immunotherapeutics (MLTX)
Goldman Sachs Analyst forecast on ALKS
Andrea Newkirk
Goldman Sachs
Goldman Sachs
$50
Hold
1.61%
Upside
Initiated
09/24/26
Alkermes (ALKS) Gets a Hold from Goldman Sachs
Mizuho Securities Analyst forecast on ALKS
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$65
Buy
32.09%
Upside
Reiterated
09/22/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: AnaptysBio (NASDAQ: ANAB), Alkermes (NASDAQ: ALKS) and Iradimed (NASDAQ: IRMD)
Jefferies Analyst forecast on ALKS
Akash Tewari
Jefferies
Jefferies
$78→$83
Buy
68.66%
Upside
Reiterated
09/22/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Robert W. Baird Analyst forecast on ALKS
Luke Herrmann
Robert W. Baird
Robert W. Baird
$58→$61
Buy
23.96%
Upside
Reiterated
09/22/26
Alkermes price target raised to $61 from $58 at BairdAlkermes price target raised to $61 from $58 at Baird
H.C. Wainwright Analyst forecast on ALKS
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$43
Hold
-12.62%
Downside
Reiterated
09/21/26
Alkermes: Orexin Franchise Proof-of-Concept Supports Balanced Risk-Reward; Hold Rating Reiterated with Unchanged $43 Price Target
J.P. Morgan Analyst forecast on ALKS
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Hold
―
Reiterated
09/21/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Wells Fargo Analyst forecast on ALKS
Benjamin Burnett
Wells Fargo
Wells Fargo
$65
Buy
32.09%
Upside
Assigned
07/29/26
Wells Fargo Gives a Buy Rating to Alkermes (ALKS)
TD Cowen Analyst forecast on ALKS
Joseph Thome
TD Cowen
TD Cowen
$57→$58
Buy
17.86%
Upside
Reiterated
07/28/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on ALKS
Ashwani Verma
UBS
UBS
$42→$48
Buy
-2.46%
Downside
Reiterated
05/06/26
Alkermes price target raised to $48 from $42 at UBSAlkermes price target raised to $48 from $42 at UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
OVIDOvid Therapeutics
OMCLOmnicell
IMUXImmunic
HITIHigh Tide
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alkermes

3 Months
Leonid TimashevRBC Capital
Success Rate
8/11 ratings generated profit
73%
Average Return
+10.82%
Copying Leonid Timashev's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +10.82% per trade.
1 Year
Paul MatteisStifel Nicolaus
Success Rate
11/13 ratings generated profit
85%
Average Return
+27.44%
Copying Paul Matteis's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +27.44% per trade.
2 Years
Joseph ThomeTD Cowen
Success Rate
17/19 ratings generated profit
89%
Average Return
+34.39%
Copying Joseph Thome's trades and holding each position for 2 Years would result in 89.47% of your transactions generating a profit, with an average return of +34.39% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALKS Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
1
0
0
3
5
Buy
31
40
28
21
9
Hold
4
8
6
8
3
Sell
1
3
3
3
2
Strong Sell
0
0
0
0
0
total
37
51
37
35
19
In the current month, ALKS has received 14 Buy Ratings, 3 Hold Ratings, and 2 Sell Ratings. ALKS average Analyst price target in the past 3 months is 58.77.
Each month's total comprises the sum of three months' worth of ratings.

ALKS Financial Forecast

ALKS Earnings Forecast

Next quarter’s earnings estimate for ALKS is -$0.08 with a range of -$0.15 to $0.00. The previous quarter’s EPS was $0.00. ALKS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.
Next quarter’s earnings estimate for ALKS is -$0.08 with a range of -$0.15 to $0.00. The previous quarter’s EPS was $0.00. ALKS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.

ALKS Sales Forecast

Next quarter’s sales forecast for ALKS is $463.61M with a range of $444.97M to $481.82M. The previous quarter’s sales results were $496.01M. ALKS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.
Next quarter’s sales forecast for ALKS is $463.61M with a range of $444.97M to $481.82M. The previous quarter’s sales results were $496.01M. ALKS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.

ALKS Stock Forecast FAQ

What is ALKS’s average 12-month price target, according to analysts?
Based on analyst ratings, Alkermes’s 12-month average price target is 58.77.
    What is ALKS’s upside potential, based on the analysts’ average price target?
    Alkermes has 19.43% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ALKS a Buy, Sell or Hold?
          Alkermes has a consensus rating of Moderate Buy which is based on 10 buy ratings, 3 hold ratings and 1 sell ratings.
            What is Alkermes’s price target?
            The average price target for Alkermes is 58.77. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $83.00 ,the lowest forecast is $38.00. The average price target represents 19.43% Increase from the current price of $49.21.
              What do analysts say about Alkermes?
              Alkermes’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of ALKS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.